FDA Grants Accelerated Approval to Atrasentan for IgA Nephropathy Dr. Kamal Kant Kohli5 April 2025 9:30 AM ISTThe US FDA has granted accelerated approval to atrasentan (Vanrafia) for reducing proteinuria in adults with primary immunoglobulin A (IgA)...
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Ruchika Sharma3 April 2025 4:30 PM ISTEast Hanover: Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia...
Atrasentan Enhances Insulin Sensitivity in Type 2 Diabetes Patients with Chronic Kidney Disease: Study Reveals Medha Baranwal30 Nov 2024 9:00 AM ISTNetherlands: A recent study, published in Diabetes, Obesity and Metabolism has revealed that atrasentan, an endothelin receptor antagonist,...
Atrasentan found superior to placebo for proteinuria reduction in the Phase 3 Trial for IgA Nephropathy. Dr Kartikeya Kohli4 Nov 2023 11:15 AM ISTIgA nephropathy (IgAN) is an autoimmune disorder wherein clusters of antibodies get deposited in the kidneys, leading to inflammation and damage to...
Novartis concludes acquisition of Chinook Therapeutics Ruchika Sharma13 Aug 2023 12:00 PM ISTBasel: Novartis has announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company...
Novartis to acquire Chinook Therapeutics for up to USD 3.5 billion in boost to late stage pipeline Ruchika Sharma12 Jun 2023 1:00 PM ISTBasel: Novartis said on Monday it agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to USD 3.5 billion to boost its...
Atrasentan reduces triglycerides, albuminuria, and LDL-C in patients with type 2 diabetes and CKD Medha Baranwal8 Dec 2022 8:00 PM ISTNetherlands: In high-risk patients with type 2 diabetes (T2D) and CKD (chronic kidney disease), atrasentan provides cardioprotection, is the...
